

The production and printing of this supplement was paid for by Merck Sharp & Dohme Ltd. Merck Sharp & Dohme Ltd also had the opportunity to review the content.

## UK medical eligibility criteria for contraceptive use

Cardiovascular disease and common cardiovascular risk factors, and hormonal/intrauterine contraception<sup>3</sup>

	CHC	POP	DMPA/NET-EN	IMP	Cu-IUD	LNG-IUD
<b>Concurrent or history of cardiovascular disease</b>						
Adequately controlled hypertension (with no other risk factors)	3	1	2	1	1	1
CHD	4	2 (initiation) 3 (continuation)	3	2 (initiation) 3 (continuation)	1	2 (initiation) 3 (continuation)
Stroke/TIA	4	2 (initiation) 3 (continuation)	3	2 (initiation) 3 (continuation)	1	2 (initiation) 3 (continuation)
Hyperlipidaemia (depending on type, severity and other CVD risk factors)	2/3	2	2	2	1	2
<b>Cardiovascular risk factors</b>						
<b>Age (years)</b>						
≥40 years	2*	1		1	1	1
18-45 years			1			
>45 years			2*			
<b>Smoking</b>						
Age <35	2	1	1	1	1	1
Age ≥35 + <15 cigarettes/day	3	1	1	1	1	1
Age ≥35 + ≥15 cigarettes/day	4	1	1	1	1	1
Age ≥35 + stopped <1 year ago	3	1	1	1	1	1
Age ≥35 + stopped ≥1 year ago	2	1	1	1	1	1
<b>Obesity (assessed using BMI)</b>						
≥30-34 Kg/m <sup>2</sup>	2	1	1	1	1	1
≥35 Kg/m <sup>2</sup>	3	1	1	1	1	1
Multiple risk factors for cardiovascular disease (e.g. older age, hypertension, smoking, obesity)	3/4**	2	3	2	1	2
Migraine with aura, at any age	4	2	2	2	1	2
Last episode ≥5 years ago	3	2	2	2	1	2
<b>Diabetes</b>						
History of gestational diabetes	1	1	1	1	1	1
Non-vascular disease (insulin or non-insulin dependent)	2	2	2	2	1	2
Nephropathy/retinopathy/neuropathy/other vascular disease	3/4	2	3	2	1	2
History of gestational hypertension (where current BP is normal)	2	1	1	1	1	1

\* FSRH CEU guideline recommends switching to other methods at the age of 50 years.

\*\* Peripheral arterial disease appears in the UKMEC under hypertension: vascular disease, with the same eligibility category as current or previous history of CHD or Stroke/TIA

CHC=combined hormonal contraception

POP=progestogen-only pill

DMPA=depot medroxyprogesterone acetate

IMP=implant(progestogen-only)

NET-EN=norethisterone enantate

Cu-IUD=copper-bearing intrauterine device

LNG-IUD=levonorgestrel-releasing intrauterine system

UKMEC-UK medical eligibility criteria

**Definition of UKMEC categories:**

**UKMEC 1:** A condition for which there is no restriction on the use of the contraceptive method

**UKMEC 2:** A condition where the advantages of using the method generally outweigh the theoretical or proven risks

**UKMEC 3:** a condition where the theoretical or proven risks generally outweigh the advantages of using the method. The provision of a method requires expert clinical judgment and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or acceptable

**UKMEC 4:** A condition that represents an unacceptable risk if the contraceptive method is used

Faculty of Sexual & Reproductive Healthcare. UK medical eligibility criteria for contraceptive use.

FSRH, 2009.

Reproduced with kind permission of FSRH



The production and printing of this supplement was paid for by Merck Sharp & Dohme Ltd. Merck Sharp & Dohme Ltd also had the opportunity to review the content.

# Contraceptive choices for women with cardiovascular risk factors

## GPs need to balance the risks against the benefits when advising women on contraceptive options, especially in women with risk factors for cardiovascular disease (CVD)

Cardiovascular disease is relatively uncommon in women of reproductive age, but some 5.5% of 25-34 and 11.8% of 45-54 year-old women have CVD,<sup>1</sup> and CVD is the third most common cause of death in women aged 45-54 years.<sup>2</sup>

Major risk factors for CVD, such as smoking and obesity, are common in women of reproductive age – 20-30% of women aged 16-54 smoke<sup>1</sup> and 30-62% are overweight or obese.<sup>1</sup>

### Contraceptive options

Factors that influence a women's choice of contraceptive method include user acceptability, efficacy, non-contraceptive benefits and side-effects but the risks of each method must be balanced against benefits on an individual basis.

The UK Medical Eligibility Criteria (UKMEC) provides an evidence-based resource for guiding clinical decision making.<sup>3</sup> It classifies the risk of contraceptive methods in the context of different medical conditions or risk factors. The criteria for CVD/CVD risk factors are shown overleaf.

More detailed information about the health risks and benefits of individual methods is available from the Faculty of Sexual and Reproductive Health Clinical Effectiveness Unit.<sup>4</sup>

Clinicians should ensure that they have an up to date clinical history (including: medical conditions, medication use, family history and CVD risk factors) and have documented a blood pressure measurement and BMI assessment. This will allow clinicians to fully assess eligibility for contraceptive use.

### Combined hormonal contraception

Oestrogen-containing contraception has been associated with an increased risk of CVD<sup>5,7</sup> which appears to be compounded by risk factors such as increased age, smoking, hypertension and migraine with aura.<sup>5,8</sup> Particular care must be taken when initiating or continuing combined methods in women with these CVD risk factors.

### Progestogen-only pills (POPs)

There is little evidence to suggest that progestogen-only methods are associated with an increased risk of stroke<sup>9</sup> or MI.<sup>10</sup> However, there is theoretically a small increased risk in women with CVD/CVD risk factors<sup>11</sup> because of the adverse effect that progestogens have on lipid metabolism.<sup>5</sup> Even in women with multiple risk factors for CVD, the advantages of progestogen-only pills (POPs) generally outweigh the risks.<sup>3</sup> There is no evidence of a causal association between POPs use and weight change or headache. In addition POPs may be appropriate in women of any age with a history of migraine (with or without aura).<sup>11</sup>

### Long-acting reversible contraception (LARC)

NICE advises that all women requesting contraception are informed of the benefits of LARC in view of their lower failure rates.<sup>12</sup> Eligibility criteria are summarised overleaf.

**Dr Cathy Johnman is a clinical lecturer public health and a speciality doctor in sexual and reproductive health at the University of Glasgow and NHS Lanarkshire. The assistance of Julie Craik, Clinical Effectiveness Unit researcher, in the preparation of this article is gratefully acknowledged.**

### References

- 1 Joint Health Surveys Unit. Health Survey for England 2006: CVD and risk factors adults, obesity and risk factors children. London: HMSO; 2008.
- 2 British Heart Foundation Heart Stats <http://www.heartstats.org/datapage.asp?id=713> (accessed 07/03/2011)
- 3 Faculty of Sexual & Reproductive Healthcare. UK medical eligibility criteria for contraceptive use: UKMEC 2009. London: FSRH; 2009.

- Available at: [www.fsrh.org/admin/uploads/UKMEC2009.pdf](http://www.fsrh.org/admin/uploads/UKMEC2009.pdf)
- 4 Faculty of Sexual & Reproductive Healthcare. CEU Method specific guidance. Available at: <http://www.ffprhc.org.uk/default.asp?Section=Publications&SubSection=ClinicalGuidance2>
  - 5 Faculty of Sexual & Reproductive Healthcare. Contraception for women aged over 40 years. London: FSRH; 2010. Available at: [www.fsrh.org/admin/uploads/ContraceptionOver40July10.pdf](http://www.fsrh.org/admin/uploads/ContraceptionOver40July10.pdf)

- 6 Croft P, BMJ 1989; 298: 165-168.
- 7 WHO Lancet 1996; 348: 498-505.
- 8 Faculty of Sexual & Reproductive Healthcare. First prescription of combined oral contraception. Available at [www.ffprhc.org.uk/admin/uploads/FirstPrescCombOralContJan06.pdf](http://www.ffprhc.org.uk/admin/uploads/FirstPrescCombOralContJan06.pdf)
- 9 Chakhtoura Z et al. Stroke 2009; 40: 1059-62.
- 10 World Health Organization. Contraception 1998; 57: 315-24.

- 11 Faculty of Sexual & Reproductive Healthcare. Progestogen only pills. Updated 2009. Available at: <http://www.ffprhc.org.uk/admin/uploads/CEUGuidanceProgestogenOnlyPill09.pdf>
- 12 NICE. Long-acting reversible contraception. Clinical Guideline 30. Available at: <http://www.nice.org.uk/CG030>